Home
Live Updates
Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO? and its combination with ezetimibe, NUSTENDI?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk : comparemela.com
Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO? and its combination with ezetimibe, NUSTENDI?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk
NILEMDO? (bempedoic acid), a first-in-class, oral treatment and NUSTENDI? (bempedoic acid ezetimibe fixed-dose combination) receive label update approval from the European Commission as treatments
Related Keywords
Italy ,
Milan ,
Lombardia ,
United Kingdom ,
Turkey ,
Switzerland ,
Daiichi Sankyo Europe Gmb ,
Sheldon Koenig ,
Alberico Catapano ,
Gillian Dsouza ,
Daiichi Sankyo ,
Oliver Appelhans ,
Daiichi Sankyo Europe ,
University Of Milan ,
European Atherosclerosis Society ,
European Society Of Cardiology ,
European Medicines Agency ,
European Commission ,
Head Of Europe Specialty Division ,
Esperion Therapeutics Inc ,
European Commissionas ,
Sankyo Europe Gmbh ,
Esperion Therapeutics ,
Europe Specialty Division ,
Professor Alberico Catapano ,
Cholesterol Lowering ,
Bempedoic Acid ,
Inhibiting Regimen ,
Sankyo Europe ,
European Economic Area ,
Marketing Authorisation Holder ,
Task Force ,
European Society ,
Cardiovascular Disease Statistics ,
Cardiovascular Outcomes ,
Public Relations ,
Specialty Medicines ,
Ihr Portfolio ,
comparemela.com © 2020. All Rights Reserved.